During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

Number 4: In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.